An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor (NCT01557348), a registered phase not stated study. The primary outcome is Least Squares Mean Change From Baseline in Disease Activity Score (3 Variables)-Erythrocyte Sedimentation Rate at Month 6.

2. Clinical Question

The study concerns a treatment decision after an inadequate response or intolerance to a previous TNF-inhibitor. It compares the disease-activity measure following a change to rituximab with the measure following a change to an alternative TNF-inhibitor. Because treatment was given in routine practice rather than assigned by a stated randomization process, the comparison describes outcomes in the recorded groups; it does not, by itself, establish that any difference was caused by the treatment choice.

The record describes follow-up for 12 months from the start of the second biologic therapy. Its primary endpoint is at Month 6, while listed secondary outcomes include measures at Month 6 and Month 12. The registry record does not report numerical results for the primary endpoint, so the size, direction, and precision of the observed group changes cannot be assessed from the information recorded.

3. Trial Design

This was a global, multi-centre, prospective, observational study in rheumatoid arthritis. It is marked completed, with a recorded enrollment of 1239. The study start is recorded as 2009-06 and primary completion as 2012-03. The registry record describes participants receiving a second biologic therapy in routine clinical practice and being observed from the start of that therapy for 12 months.

The two treatment groups were rituximab and an alternative TNF-inhibitor. The record does not state how treatment allocation occurred. It explicitly identifies the study as not randomized and cautions that the arms are not a like-for-like control comparison. This matters because people receiving different therapies in routine care may differ in ways that also relate to disease activity and subsequent outcomes. The record does not report a method for controlling such differences.

The primary outcome was least-squares mean change from baseline in DAS28-3 (ESR) at Month 6. The primary effectiveness population was defined by treatment receipt, having only one previous biologic therapy, and contributing to the 24-week primary endpoint analysis. This is not necessarily identical to the full enrollment population. The record does not report the number of participants included in that primary analysis or how many contributed data at each assessment.

Listed secondary outcomes cover disease activity and related measures, including joint counts, C-reactive protein, ESR, physician and patient global assessments, and participant-reported pain. These were specified at Month 6 and/or Month 12. The registry lists 18 outcome measures and 20 analyses. It does not report the statistical plan, the rationale for the enrollment target, or whether any interim analyses were planned or conducted.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Of 1239 enrolled participants, 9 had no information on second biologic treatment/reasons for discontinuing prior tumor necrosis factor inhibitor (TNFi), 1111 had one previous TNFi,119 had more than one previous TNFi. Of 1111 participants, 728 were considered for primary effectiveness analysis (405 in Rituximab arm and 323 in Alternative TNFi arm).

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The primary effectiveness population included all participants who received at least one dose of a second biologic therapy at Baseline, had only one previous biologic therapy, and contributed to 24-week DAS28-ESR primary endpoint analysis.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The primary effectiveness population included all participants who received at least one dose of a second biologic therapy at baseline (day of change in biologic therapy \[\<=Day 1\]), had only one previous biologic therapy, and contributed for 24-week disease activity score 28 (DAS28)-erythrocyte sedimentation rate (ESR) for primary analysis.

6. Primary Endpoint

The registry lists the primary outcome as Least Squares Mean Change From Baseline in Disease Activity Score (3 Variables)-Erythrocyte Sedimentation Rate at Month 6, measured over Baseline (Day of change in biologic therapy [<=Day 1]) and Month 6.

The primary endpoint is the least-squares mean change from baseline in the Disease Activity Score using three variables and erythrocyte sedimentation rate (DAS28-3 (ESR)) at Month 6. Baseline is defined as the day of change in biologic therapy, at or before Day 1. The measure combines tender and swollen joint counts using 28 joints and ESR. Its score ranges from 0 to 9.4; higher scores indicate more disease activity, and a decrease indicates improvement in disease activity.

In general, a change-from-baseline endpoint expresses how a measured value differs from its starting value. It can describe the direction and size of change during follow-up, while the comparison between groups addresses whether those changes differ. A least-squares mean is a model-based mean estimate; interpretation depends on the model and any adjustments used. The registry record does not report the model details or numerical estimates for this endpoint.

The endpoint is used to summarize disease activity through joint counts and an inflammation marker. The registry record identifies the outcome, scale, and timeframe, but does not report group-specific changes, a between-group contrast, confidence intervals, or a significance test. Therefore the direction, magnitude, and precision of the primary result are not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record reports a continuous primary outcome summarized as a least-squares mean change, with standard error as the stated dispersion measure. It does not report the fitted model, adjustment variables, hypothesis test, confidence interval, or p-value. Those omissions limit what can be inferred about how the estimates were obtained and how precisely they were estimated.

What does a least-squares mean represent?

In general, a least-squares mean is a model-based estimate of an average. Unlike a simple arithmetic mean, it may reflect adjustment for other variables included in the model. Its interpretation depends on which variables and assumptions were used. Since those details are not reported in the registry record, the extent or nature of any adjustment cannot be determined. The term alone does not show that baseline differences between the observational groups were adequately controlled.

The endpoint is a change from baseline in DAS28-3 (ESR) at Month 6. A change score relates a follow-up value to the baseline value for the outcome. The registry specifies that baseline was measured on the day of change in biologic therapy, at or before Day 1. It does not report how baseline values or follow-up observations were handled when data were unavailable, nor does it report the number of observations contributing to each estimate.

How should the standard error be read?

In general, a standard error describes the statistical precision of an estimated quantity under the analysis model. It is not the spread of individual participants' measurements. Smaller standard errors generally indicate greater precision for a particular estimate, while larger ones indicate less precision. A standard error alone is not a complete account of uncertainty: a confidence interval or a clearly specified test is often needed to interpret an estimate. The registry record names standard error as the dispersion measure but does not report the endpoint estimates or their standard errors.

General statistical context: a confidence interval is an interval estimate constructed using data and an analysis method. Its width reflects uncertainty under the method's assumptions. For an observational comparison, a narrow interval would not eliminate bias from differences between treatment groups. Precision and validity are separate concerns: a result can be precisely estimated yet still be affected by confounding or selection.

What does the observational comparison allow?

The study compares treatment groups formed in routine clinical practice; it is not randomized, and allocation is not stated. In general, randomization is a design method for balancing known and unknown factors between groups in expectation. Without random assignment, groups may differ at the start or in care patterns. Statistical adjustment can sometimes address measured differences, but it cannot guarantee control of unmeasured factors. The registry record does not report which adjustment methods, if any, were used.

The primary analysis population required at least one dose of a second biologic therapy at baseline, only one previous biologic therapy, and contribution to the 24-week primary endpoint analysis. This definition clarifies who was eligible for the primary effectiveness analysis, but the record does not give the number meeting those criteria. It also does not state whether participants were analyzed according to the therapy they started if they later changed or stopped treatment.

How should planning illustrations be understood?

General statistical context: a sample-size calculation is a planning exercise based on assumptions about the effect to detect, variability, allocation, significance level, and analysis method. The registry record describes the planning illustrations as using a two-sided significance level of 0.05, equal allocation between groups, and a normal approximation. They are based on the observed effect, with the effect to detect expressed as a stated fraction of that effect. They are illustrations, not the study's reported design rationale and not observed power. The record does not report a sample-size justification for the original study.

The record specifies that non-time-to-event planning values are expressed as participants per arm. This is distinct from the recorded enrollment and from the number included in the primary analysis. No planning estimate should be read as a count of participants who actually contributed data, or as evidence that a result was likely or unlikely to be statistically significant.

What is not reported about the analysis?

The statistical analysis plan is not reported in the registry record. Neither are the model specification, covariates, treatment of repeated measurements, method for missing data, multiplicity procedure, or any interim-analysis plan. The record lists 18 outcome measures and 20 analyses, but those counts do not reveal which tests were primary for decision-making or how multiple comparisons were handled. In general, testing many outcomes can increase the chance of at least one apparently notable result unless the analysis accounts for multiplicity. Without a reported strategy, that issue cannot be assessed for this study.

No numerical primary endpoint estimate or group contrast is reported. Therefore, readers cannot use the record to reproduce the analysis, evaluate its precision, or judge whether model assumptions were met. These are limits of what the registry record reports, not evidence that a particular method was or was not used.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Rituximab", "Alternative TNFi")
n   <- c(405, 323)
m   <- c(-1.5, -1.1)
sp  <- c(0.22, 0.23)
sd  <- sp * sqrt(n)      # standard errors converted to SDs
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Rituximab  405  -1.500  4.427  -1.932  -1.068
CARM  Alternative TNFi  323  -1.100  4.134  -1.552  -0.648

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists 18 outcome measures and 20 analyses. The primary endpoint is specified as least-squares mean change in DAS28-3 (ESR) at Month 6, and several secondary outcomes are listed at Month 6 and Month 12. However, the statistical plan and any method for addressing multiple comparisons are not reported in the registry record. The number of outcomes alone does not indicate which comparisons were considered confirmatory or whether any adjustment was planned.

General statistical context: when many outcomes or comparisons are examined, the chance of finding at least one apparently unusual result can increase. A prespecified hierarchy or multiplicity adjustment can help manage this issue. Without the study's analysis plan, readers cannot determine whether such methods were used or how to interpret secondary findings. Numerical results for the listed outcomes are not reported in the registry record, so their direction and uncertainty cannot be evaluated.

Missing-data methods are also not reported in the registry record. The primary effectiveness population included participants who contributed to the 24-week endpoint analysis, but the record does not state how missing measurements were handled, how many participants lacked endpoint data, or whether missingness differed by treatment group. In general, missing data can affect an estimate when the probability of having a measurement is related to participant characteristics or outcomes.

The record defines the primary analysis population but does not report analysis details such as the treatment of discontinuation, switching, or other departures from the initial therapy. It also does not report an interim-analysis plan or sample-size justification. These omissions prevent assessment of how analysis choices may have influenced the reported findings.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 2% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: rheumatoid arthritis (1.6%), osteoarthritis (1.0%), pneumonia (0.7%), urinary tract infection (0.7%), arthralgia (0.6%).

The safety entries distinguish serious adverse events from other adverse events and give, for each treatment group, the number at risk and the number recorded as affected. For serious adverse events, the registry records 604 at risk and 82 affected in the rituximab group, and 507 at risk and 56 affected in the alternative TNFi group. For other adverse events, it records 604 at risk and 79 affected in the rituximab group, and 507 at risk and 79 affected in the alternative TNFi group. These are registry counts; no comparative risk estimate or statistical test is reported.

The listed serious adverse-event terms and percentages are rheumatoid arthritis, 1.6%; osteoarthritis, 1.0%; pneumonia, 0.7%; urinary tract infection, 0.7%; arthralgia, 0.6%; and lower respiratory tract infection, 0.5%. The record does not attribute these percentages to a particular treatment group in the listed information, so they should not be treated as group-specific comparisons.

General statistical context: safety counts describe recorded events or affected entries under the registry's definitions. They do not, on their own, establish that treatment caused an event or that one treatment has greater risk. The death fields are not reported in the registry record; this is not evidence that there were no deaths. Details of event collection, attribution, and missing safety follow-up are not reported in the registry record.

13. What the Result Does, and Does Not, Mean

The record establishes that a prospective observational study compared rituximab with alternative TNF-inhibitors as second biologic therapy in people with rheumatoid arthritis after an inadequate response or intolerance to a single previous TNF-inhibitor. It specifies DAS28-3 (ESR) change at Month 6 as the primary outcome and describes how the score is interpreted. It also lists other disease-activity and symptom measures and reports selected adverse-event counts and terms.

It does not report the numerical primary outcome results. No group-specific change, between-group estimate, confidence interval, or p-value for the primary endpoint is available in the registry record. The record therefore does not establish whether disease activity changed in either group, how much it changed, or whether the groups differed. The outcome definition is not itself a finding.

The study design also limits causal interpretation. Treatment was not randomized, and allocation was not stated. In general, an observational group comparison may reflect differences in who received each treatment as well as differences associated with treatment. The record does not report the analysis methods needed to evaluate adjustment for those differences. Even a reported association would require interpretation in light of that design.

The adverse-event counts describe entries recorded for the groups, but do not establish causality or a comparative safety effect. Listed serious-event terms are not assigned to a treatment group in the record, and deaths are not reported in the registry record. Missing-data handling and safety follow-up details are also not reported.

In general, a result is most informative when its estimate, uncertainty, analysis population, and methods are all clear. Here, the registry provides design and endpoint definitions but not efficacy estimates or key analysis details. It supports understanding what the study set out to observe, not a conclusion about which treatment produced a better outcome.

14. Why This Trial Matters Statistically

This study is statistically relevant because it addresses a comparison made in routine care after a previous TNF-inhibitor did not work adequately or was not tolerated. Its prospective observation and defined follow-up give context for the intended comparison, while the primary endpoint focuses on change in a disease-activity score at Month 6.

It also illustrates why the design must be considered alongside an outcome measure. The two groups were not randomized, and allocation was not stated. General statistical context: randomized allocation can reduce systematic baseline differences, whereas routine-care comparisons can retain differences related to treatment choice. Analytical adjustment may address measured factors, but the registry record does not report whether or how it was used. A group contrast in such a study would not automatically be a causal treatment effect.

The endpoint definition is informative: DAS28-3 (ESR) combines joint counts and ESR, and a decrease is defined as improvement in disease activity. Yet an endpoint definition does not substitute for observed estimates. The registry record does not report numerical efficacy outcomes, uncertainty intervals, or tests. This distinction is important for readers: the study question and outcome can be clear even when the evidence needed to answer the question is not recorded.

The record also lists multiple outcomes across follow-up times, but does not report a multiplicity strategy, missing-data methods, or the statistical analysis plan. These omissions matter because analysis choices affect interpretation, particularly when outcomes are numerous and the primary analysis population is defined by endpoint contribution. The entry therefore highlights the value of complete reporting of estimates, uncertainty, analysis populations, and methods alongside study design.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most consequential limitation of the registry record is that it does not report numerical results for the primary endpoint or the listed secondary outcomes. Without estimates and uncertainty measures, the direction, magnitude, and precision of observed changes cannot be assessed. The study's outcome definitions do not reveal what the data showed.

The comparison is observational, not randomized, and allocation is not stated. The record explicitly cautions that the arms are not a like-for-like control comparison. Differences between people receiving each treatment could influence outcomes, and the registry record does not report an adjustment strategy or details that would allow readers to judge control of confounding.

The primary effectiveness population was restricted to people who received at least one dose of second biologic therapy, had only one previous biologic therapy, and contributed to the 24-week endpoint analysis. The number meeting those criteria and the number with endpoint data are not reported in the registry record. Missing-data handling, treatment of therapy changes or discontinuation, and the completeness of follow-up are also not reported.

The statistical plan is not reported. In particular, the record does not describe the model behind the least-squares means, covariate adjustment, confidence-interval or testing procedures, multiplicity handling, interim analyses, or sample-size justification. The record describes planning illustrations, but these are not the study's reported design rationale and are not observed power.

Safety information is limited to the listed counts and terms. The registry record does not report deaths in the death fields, group attribution for the listed serious-event percentages, or details of event ascertainment. The counts should therefore be interpreted descriptively rather than as evidence of a causal difference between treatments.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor — NCT01557348.
• Registry record last updated 2017-01-24; status last verified 2016-11.
• Results first posted 2017-01-24.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

This completed, prospective, global multi-centre observational study examined rituximab and alternative TNF-inhibitors as second biologic therapy in rheumatoid arthritis after an inadequate response or intolerance to a single previous TNF-inhibitor. Enrollment is recorded as 1239. The study start is 2009-06 and primary completion is 2012-03; follow-up was described as 12 months from the start of second biologic therapy.

The primary endpoint was least-squares mean change in DAS28-3 (ESR) at Month 6. The registry defines the score and identifies a decrease as improvement, but does not report numerical primary or secondary outcome results. Treatment allocation was not stated, and the comparison was not randomized. The record also does not report the statistical analysis plan, missing-data methods, or multiplicity handling.

Serious and other adverse-event counts are recorded for both groups, with a list of serious-event terms and percentages. These entries do not establish comparative or causal safety effects. Overall, the record describes the question, design, and endpoints, but does not contain the efficacy results needed to assess the treatment comparison.